Axsome Therapeutics Resolves Sunosi Patent Case With Hikma

MT Newswires Live

Mar 05

Axsome Therapeutics (AXSM) said Wednesday it has reached a settlement with Hikma Pharmaceuticals resolving a patent dispute over its treatment Sunosi (solriamfetol.)

The dispute arose after Hikma filed an abbreviated new drug application seeking Food and Drug Administration approval to produce a generic version of Sunosi, the company said.

As part of the agreement, Axsome said it will grant Hikma a license to launch its generic version no earlier than March 1, 2040, or Sept. 1, 2040, if pediatric exclusivity is granted, pending regulatory approval.

Axsome said the settlement will be submitted for review by the US Federal Trade Commission and the Department of Justice.

The company said similar patent litigation against other parties related to Sunosi remains pending in the US District Court for the District of New Jersey.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2517919070"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2517919070\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2517919070?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-05 21:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2517919070","market":"hk","top_or_hot":-1,"title":"Axsome Therapeutics Resolves Sunosi Patent Case With Hikma","media":"MT Newswires Live","content":"<html><body><p> Axsome <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (AXSM) said Wednesday it has reached a settlement with Hikma Pharmaceuticals resolving a patent dispute over its treatment Sunosi (solriamfetol.)</p><p>The dispute arose after Hikma filed an abbreviated new drug application seeking Food and Drug Administration approval to produce a generic version of Sunosi, the company said.</p><p>As part of the agreement, Axsome said it will grant Hikma a license to launch its generic version no earlier than March 1, 2040, or Sept. 1, 2040, if pediatric exclusivity is granted, pending regulatory approval.</p><p>Axsome said the settlement will be submitted for review by the US Federal Trade Commission and the Department of Justice.</p><p>The company said similar patent litigation against other parties related to Sunosi remains pending in the US District Court for the District of New Jersey.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Axsome Therapeutics Resolves Sunosi Patent Case With Hikma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAxsome Therapeutics Resolves Sunosi Patent Case With Hikma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-05 21:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Axsome <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (AXSM) said Wednesday it has reached a settlement with Hikma Pharmaceuticals resolving a patent dispute over its treatment Sunosi (solriamfetol.)</p><p>The dispute arose after Hikma filed an abbreviated new drug application seeking Food and Drug Administration approval to produce a generic version of Sunosi, the company said.</p><p>As part of the agreement, Axsome said it will grant Hikma a license to launch its generic version no earlier than March 1, 2040, or Sept. 1, 2040, if pediatric exclusivity is granted, pending regulatory approval.</p><p>Axsome said the settlement will be submitted for review by the US Federal Trade Commission and the Department of Justice.</p><p>The company said similar patent litigation against other parties related to Sunosi remains pending in the US District Court for the District of New Jersey.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AXSM","symbol_name":"Axsome Therapeutics, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2517919070","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2517919070","pubTimestamp":1741179964,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Axsome Therapeutics  said Wednesday it has reached a settlement with Hikma Pharmaceuticals resolving a patent dispute over its treatment Sunosi The dispute arose after Hikma filed an abbreviated new drug application seeking Food and Drug Administration approval to produce a generic version of Sunosi, the company said.As part of the agreement, Axsome said it will grant Hikma a license to launch its generic version no earlier than March 1, 2040, or Sept. 1, 2040, if pediatric exclusivity is granted, pending regulatory approval.Axsome said the settlement will be submitted for review by the US Federal Trade Commission and the Department of Justice.The company said similar patent litigation against other parties related to Sunosi remains pending in the US District Court for the District of New Jersey.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AXSM":"Axsome Therapeutics, Inc.","BK4585":"ETF&股票定投概念","BK4007":"制药","BK4505":"高瓴资本持仓"},"translate_title":"Axsome Therapeutics与Hikma解决Sunosi专利案","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AXSM":0.6},"content_text":"Axsome Therapeutics (AXSM) said Wednesday it has reached a settlement with Hikma Pharmaceuticals resolving a patent dispute over its treatment Sunosi (solriamfetol.)The dispute arose after Hikma filed an abbreviated new drug application seeking Food and Drug Administration approval to produce a generic version of Sunosi, the company said.As part of the agreement, Axsome said it will grant Hikma a license to launch its generic version no earlier than March 1, 2040, or Sept. 1, 2040, if pediatric exclusivity is granted, pending regulatory approval.Axsome said the settlement will be submitted for review by the US Federal Trade Commission and the Department of Justice.The company said similar patent litigation against other parties related to Sunosi remains pending in the US District Court for the District of New Jersey.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}